Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year

ABSTRACT

Background

Real-world data on guselkumab, especially at times >6 months, are limited.

Research design and methods

We performed a longitudinal, retrospective analysis on 307 patients with moderate–severe chronic plaque psoriasis (Psoriasis Area Severity Index [PASI] >10) treated with guselkumab for up to 12 months.

Main outcome measures

PASI 75, PASI 90, and PASI 100 were assessed at baseline and at 4, 12, 20, 28, 36, 44, and 52 weeks.

Results

At 12 weeks, PASI 75, PASI 90, and PASI 100 were achieved in 56.4%, 33.6%, and 24.1% of patients, respectively. At 52 weeks, PASI 75, PASI 90, and PASI 100 were achieved in 82.7%, 68.7%, and 51.1% of patients, respectively. Patients without comorbidities and those naïve to previous biological therapy had better responses. The mean Dermatology Life Quality Index score decreased from 14.0 at baseline to 3.1 at 12 weeks and 1.6 at 6 months, which was maintained at later times. Similar improvements were seen in pruritus visual analog scale.

Conclusions

Guselkumab maintains its efficacy for up to 12 months among responders in a real-world cohort of patients with moderate–severe plaque psoriasis, confirming data from prior real-world studies with smaller cohorts and shorter duration of follow-up.

KEYWORDS:

• Guselkumab
• efficacy
• plaque psoriasis
• treatment
• real-world

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

A reviewer on this manuscript has disclosed that they have worked on clinical trials for ustekinumab and guselkumab but that they are not an advisor for the company. They have acted as an advisor for Abbvie, Bristol-Myers Squibb, Amgen and Eli Lilly and have worked on clinical trials for Abbvie, Bristol-Myers Squibb, Amgen, Eli Lilly and Union Chimique Belge. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.

Supplementary material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/14712598.2022.2090835

Additional information

Funding

This paper was not funded.